Therapeutic Indications

Bicalutamide is indicated for:

Prostate cancer

Men inly, only Adults (18 years old or older)

Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression.

Bicalutamide is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 150 mg once a day

Contraindications

Active ingredient Bicalutamide is contraindicated in the following cases:

Lactation

No gender/age discrimination

Bicalutamide is contraindicated during breast-feeding.

Pregnancy

No gender/age discrimination

Bicalutamide is contraindicated in females and must not be given to pregnant women.

Terfenadine, astemizole, cisapride

No gender/age discrimination

Bicalutamide must not be given to any patient who has shown a hypersensitivity reaction to the active substance or to any of the excipients of this product. Co-administration of terfenadine, astemizole or cisapride with bicalutamide is contraindicated. Moreover, bicalutamide is contraindicated in females and must not be given to pregnant women or nursing mothers.